South Korea's Ministry of Food and Drug Safety announced plans to raise application fees for biosimilar drug approvals significantly while expediting review timelines beginning next year. This regulatory shift aims to accelerate biosimilar availability and encourage market competition in the biopharmaceutical sector, signaling proactive measures to support biotech growth in the region.